Advertisement
News
Advertisement

Metamark, HistoRx join in personalized cancer treatment licensing deal

Mon, 12/20/2010 - 9:32am
Mass High Tech: The Journal of New England Technology

Molecular diagnostics startup Metamark Genetics Inc. has won a worldwide license to sell its MetamarkDx Prognostic Assay, using technology from Branford, Conn.-based HistoRx Inc., a tissue-based diagnostics firm.

The Cambridge startup has been working with HistoRx to add the Connecticut firm’s AQUA technology, a tissue biomarker analysis platform, to the assays for the purpose of analyzing the molecular structure of individual tumors. The worldwide license refers specifically to HistoRx’s technology for the analysis of fluorescent immunohistochemistry, which the companies noted as playing a role in assessing biomarkers for personalized treatment.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading